Cytokinetics shareholders re-elect three Class I directors and approve all four proposals at annual meeting

CYTOKINETICS INC

Edward M. Kaye, Wendell Wierenga, and Nancy J. Wysenski re-elected as Class I directors; Wierenga received 85.4M for vs 22.4M withheld.
ESPP amendment approved to increase authorized shares by 1,000,000; 107.3M for, 261k against.
Ernst & Young LLP ratified as auditor for FY 2026; 115.5M for, 269k against.
Advisory vote on executive compensation passed with 104.0M for, 3.0M against.
Quorum of 93.47% of eligible shares represented at meeting.

item 5.07

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

CYTOKINETICS INC shareholders approved Advisory Vote on Executive Compensation at the 2026-05-27 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2026-05-27

Exact text from the filing

The stockholders approved, on an advisory basis, the compensation of the named executive officers, as disclosed in the Company's Proxy Statement for the 2026 Annual Meeting of Stockholders.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

CYTOKINETICS INC shareholders approved Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of authorized shares reserved for issuance under the Amended and Restated 2015 Employee Stock Purchase Plan by 1,000,000 shares of common stock at the 2026-05-27 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2026-05-27

Exact text from the filing

The stockholders approved the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

CYTOKINETICS INC shareholders approved Election of Three Class I Directors at the 2026-05-27 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-05-27

Exact text from the filing

The stockholders elected Edward M. Kaye, M.D., Wendell Wierenga, Ph.D., and Nancy J. Wysenski as Class I Directors, each to serve for a three-year term and until their successors are duly elected and qualified or their earlier resignation or removal.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

CYTOKINETICS INC shareholders approved Ratification of Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2026 at the 2026-05-27 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-05-27

Exact text from the filing

The stockholders ratified the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

View on SEC.gov

171 shareholder votes filed in the last 30 days. Browse all shareholder votes →

CYTOKINETICS INC filing history →

Source: SEC EDGAR

accession 0001193125-26-241840

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.